Cyclerion therapeutics, inc. (CYCN)
Income statement / Yearly
Dec'19Dec'18
Revenue from related party

4,507

-

Cost and expenses:
Research and development

95,140

87,716

General and administrative

34,404

27,536

Total cost and expenses

129,544

115,252

Loss from operations

-125,037

-115,252

Interest and other income

2,029

-

Net loss

-123,008

-115,252

Net loss per share:
Basic and diluted net loss per share (in dollars per share)

-4.49

-4.21

Weighted average shares used in calculating:
Basic and diluted net loss per share (in shares)

27

27

Other comprehensive loss:
Net loss

-123,008

-115,252

Other comprehensive loss:
Foreign currency translation adjustment

-20

-

Total other comprehensive loss

-20

-

Comprehensive loss

-123,028

-115,252